Qiagen N.V.

NYSE:QGEN Lagerbericht

Marktkapitalisierung: US$9.5b

Qiagen Management

Management Kriterienprüfungen 4/4

Qiagen CEO ist Thierry Bernard , ernannt in Oct 2019, hat eine Amtszeit von 5.08 Jahren. Die jährliche Gesamtvergütung beträgt $1.99M , bestehend aus 49.1% Gehalt und 50.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.14% der Aktien des Unternehmens, im Wert von $13.73M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.8 Jahre bzw. 9.6 Jahre.

Wichtige Informationen

Thierry Bernard

Geschäftsführender

US$2.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts49.1%
Amtszeit als Geschäftsführer5.1yrs
Eigentum des Geschäftsführers0.1%
Durchschnittliche Amtszeit des Managements6.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder9.6yrs

Jüngste Management Updates

Recent updates

Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

Oct 11
Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

Sep 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

May 21
With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

May 03
Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Mar 20
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Feb 13
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Jan 23
Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

Dec 08
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Oct 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Sep 04
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jul 17
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

May 23
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Apr 18
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Feb 15
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Jan 18
If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jan 04
A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Oct 31
We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Oct 04
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Sep 14

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Thierry Bernard im Vergleich zu den Einnahmen von Qiagen verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

US$93m

Jun 30 2024n/an/a

US$73m

Mar 31 2024n/an/a

US$337m

Dec 31 2023US$2mUS$979k

US$341m

Sep 30 2023n/an/a

US$332m

Jun 30 2023n/an/a

US$337m

Mar 31 2023n/an/a

US$353m

Dec 31 2022US$10mUS$950k

US$423m

Sep 30 2022n/an/a

US$488m

Jun 30 2022n/an/a

US$539m

Mar 31 2022n/an/a

US$563m

Dec 31 2021US$2mUS$900k

US$513m

Sep 30 2021n/an/a

US$311m

Jun 30 2021n/an/a

US$480m

Mar 31 2021n/an/a

US$449m

Dec 31 2020US$2mUS$900k

US$359m

Sep 30 2020n/an/a

US$191m

Jun 30 2020n/an/a

US$14m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$1mUS$650k

-US$41m

Vergütung im Vergleich zum Markt: ThierryDie Gesamtvergütung ($USD1.99M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD7.74M).

Entschädigung vs. Einkommen: ThierryDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Thierry Bernard (60 yo)

5.1yrs

Amtszeit

US$1,991,874

Vergütung

Mr. Thierry Bernard serves as Director of Neogen Corporation since November 01, 2024. He has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board s...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Thierry Bernard
CEO, MD & Member of Management Board5.1yrsUS$1.99m0.14%
$ 13.7m
Roland Sackers
CFO, MD & Member of Management Board20.8yrsUS$1.07m0.19%
$ 17.9m
Antonio Santos
Senior VP & Head of Global Operations2.6yrskeine Datenkeine Daten
John Gilardi
Vice President of Corporate Communications & Investor Relations14.1yrskeine Datenkeine Daten
Stephany Foster
Senior VP & Head of Human Resources5.1yrskeine Datenkeine Daten
Thomas Schweins
Senior Vice President of Life Science Business Area6.8yrskeine Datenkeine Daten
Thomas Theuringer
Senior Director & Head of External Communicationsno datakeine Datenkeine Daten
Jean-Pascal Viola
Senior VP & Head of Corporate Strategy and Business Development9.5yrskeine Datenkeine Daten
Jonathan Sheldon
Senior VP & Head of the QIAGEN Digital Insights Business Area6.8yrskeine Datenkeine Daten
Fernando Beils
Senior VP & Head of the Molecular Diagnostics Business Areano datakeine Datenkeine Daten
Nitin Sood
Senior VP & Head of the Life Sciences Business Areano datakeine Datenkeine Daten

6.8yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: QGENDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.8 ).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Stephen Rusckowski
Independent Member of Supervisory Board1.6yrsUS$46.07k0.000010%
$ 950.8
Metin Colpan
Independent Member of the Supervisory Board & Vice Chair of the Scientific Advisory Board20.8yrsUS$86.50k0.080%
$ 7.6m
Elizabeth Tallett
Independent Member of the Supervisory Board13.4yrsUS$101.50k0.022%
$ 2.1m
Eva Pisa
Independent Member of the Supervisory Board2.4yrsUS$68.50kkeine Daten
Lawrence Rosen
Independent Chairman of Supervisory Board11.4yrsUS$188.50k0.0067%
$ 638.0k
Toralf Haag
Independent Member of the Supervisory Board3.8yrsUS$82.50k0.0012%
$ 112.2k
Elaine Mardis
Independent Member of the Supervisory Board10.4yrsUS$79.50k0.0018%
$ 175.0k
Peter Kaspar
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Ross Levine
Independent Member of the Supervisory Board & Chair of the Scientific Advisory Board8.8yrsUS$68.50k0.0075%
$ 716.0k
Patrice Nordmann
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Neville Sanjana
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Sarah Polonius-Teichmann
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten

9.6yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: QGENDie Vorstandsmitglieder gelten als erfahren (9.6 Jahre durchschnittliche Amtszeit).